ADARx Pharmaceuticals has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical trials of a range of next-gen small interfering RNA (siRNA) medicines.
The San Diego-based company has yet to set out how much stock it’s planning to offer—or at what price—but the lion’s share of the proceeds will go towards advancing three clinical-stage medicines.
They include bankrolling agazisiran through ongoing phase 2 studies in various complement-mediated diseases. These programs cover renal diseases like IgA nephropathy, complement 3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, as well as the rare blood disorder paroxysmal nocturnal hemoglobinuria, along with an eye condition called geographic atrophy secondary to age-related macular degeneration.
Depending on how those mid-stage studies perform, ADARx will also reserve some of the IPO proceeds to potentially kick off phase 3 studies of the complement factor B-targeting siRNA therapy in the same indications, the company explained in a Securities and Exchange Commission filing Friday.
ADARx has already taken a prekallikrein-targeted siRNA med called onvuzosiran into phase 3 development to prevent hereditary angioedema, and the IPO funds are expected to continue this study as well as “support pre-commercial activities,” according to the filing.
The final part of ADARx’s trio of clinical-stage siRNA assets is the factor XI-targeted ADX-626, which is undergoing a phase 1 study in healthy participants. The biotech is hoping the IPO will able to not only fund this trial but finance a phase 2 study of the therapy for secondary stroke prevention and an exploratory trial for stroke prevention in atrial fibrillation.
The remaining proceeds from the planned Nasdaq listing will be used to take two other siRNA therapies, the adipose-targeted obesity program ADX-077 and the Alzheimer’s disease-focused ADX-199, into the clinic next year.
The aim of siRNA meds is to prevent the production of disease-causing proteins by targeting the protein’s respective messenger RNA. ADARx has touted its therapies as offering long-lasting effects without genome alterations and the associated long-term safety concerns.
This approach has attracted interest from AbbVie, which paid $335 million upfront last year to secure options on next-gen siRNA therapeutics across several disease areas.
The hefty upfront fee from that deal was even larger than the impressive $200 million series C that ADARx brought in back in 2023. The round was backed by the likes of Blackrock, Lilly Asia Ventures, OrbiMed and SR One Capital Management
Thanks to the fundraise and the AbbVie deal, ADARx entered 2026 with $427.3 million still in the bank—although the company will need more to bankroll such a wide-ranging clinical agenda.
The biotech currently employs 100 full-time staffers, led by CEO and co-founder Zhen Li, Ph.D., a veteran of both Arrowhead Pharmaceuticals and Merck & Co. Li first hinted to Fierce that he was considering an IPO way back in 2023, but the company has clearly been biding its time.
ADARx’s leadership will likely be hoping for a similarly warm reception on the public markets to that received by the growing list of biotechs that have already gone public this year. The bumper run of IPOs in 2026 has included record-breaking listings from the likes of Parabilis Medicines and Kailera Therapeutics.
Facts Only
* ADARx Pharmaceuticals is a San Diego-based biotechnology company.
* The company is planning an initial public offering (IPO) on the Nasdaq.
* ADARx focuses on small interfering RNA (siRNA) medicines.
* Three clinical-stage medicines are being advanced: agazisiran, onvuzosiran, and ADX-626.
* Agazisiran is in phase 2 studies for complement-mediated diseases, including IgA nephropathy, complement 3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy.
* Onvuzosiran is in phase 3 development for the prevention of hereditary angioedema.
* ADX-626 is in a phase 1 study for healthy participants, with planned phase 2 studies for secondary stroke prevention and atrial fibrillation stroke prevention.
* ADX-077 (obesity) and ADX-199 (Alzheimer’s) are targeted for clinical entry in 2027.
* AbbVie paid $335 million upfront last year for options on siRNA therapeutics.
* A 2023 series C funding round raised $200 million from Blackrock, Lilly Asia Ventures, OrbiMed, and SR One Capital Management.
* ADARx had $427.3 million in cash at the start of 2026.
* CEO and co-founder Zhen Li previously worked at Arrowhead Pharmaceuticals and Merck & Co.
Executive Summary
ADARx Pharmaceuticals is preparing for a Nasdaq IPO to fund an expansive clinical pipeline of siRNA therapies designed to prevent the production of disease-causing proteins. The company is currently balancing several high-stakes programs: the phase 3 development of onvuzosiran for hereditary angioedema, phase 2 studies of agazisiran for various renal, blood, and eye disorders, and early-stage trials for ADX-626 targeting stroke prevention. Additionally, the company intends to move obesity and Alzheimer’s programs into clinical trials by next year.
Financial backing is substantial, stemming from a $200 million series C round and a $335 million upfront payment from AbbVie. Despite entering 2026 with over $427 million in liquidity, the breadth of the clinical agenda necessitates additional public capital. The timing of the IPO aligns with a broader trend of biotech listings in 2026, which have seen record-breaking performances from companies like Parabilis Medicines and Kailera Therapeutics. The ultimate success of these programs remains dependent on the outcomes of ongoing mid-stage studies.
Full Take
The strongest version of this narrative is that of a well-capitalized, scientifically disciplined biotech company timing its market entry to maximize valuation during a bullish IPO cycle. By securing a massive upfront payment from AbbVie and diversifying its pipeline across high-need areas—from rare diseases to obesity and Alzheimer’s—ADARx has minimized the binary risk typically associated with single-asset biotechs.
The narrative relies on a pattern of borrowed credibility, weaving the names of heavy-hitting investors (Blackrock, OrbiMed) and pharmaceutical giants (AbbVie) to signal legitimacy and a "guaranteed" path to success. This creates an environment where the scientific risk of siRNA—a complex modality—is secondary to the financial momentum of the "bumper run" of 2026 IPOs.
The driving paradigm is the "Platform Play," where the value is shifted from the success of a specific drug to the presumed validity of the underlying technology. The unstated assumption is that because the platform works for one indication, it will scale across vastly different pathologies (e.g., from renal disease to Alzheimer’s). This echoes the historical pattern of biotech cycles where platform enthusiasm often precedes the harsh reality of phase 3 attrition.
The primary beneficiaries are the early venture capitalists and founders who can liquidate during a market peak. The cost is borne by future public shareholders if the "platform" fails to translate into multiple approved products.
Bridge Questions:
1. How does the efficacy of siRNA in rare complement-mediated diseases correlate with its potential success in complex neurodegenerative conditions like Alzheimer’s?
2. If the 2026 IPO trend is a bubble, how does that affect the long-term viability of companies relying on public markets to fund phase 3 trials?
Counterstrike Scan: A coordinated campaign would use the names of prestigious investors to create a "Fear Of Missing Out" (FOMO) effect, urging investors to buy in before the "inevitable" success of the platform. While the text mentions the warm market, it remains largely a reporting of filings rather than a promotional pitch.
Patterns detected: none
Sentinel — Human
The text reads like a summary of a formal press release or SEC filing, efficiently reporting the pipeline strategy and financing details of a biotech company.